Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017

Stage III non-small cell lung cancer (NSCLC) accounts for around 21  % of all cases of NSCLC and clinical management is challenged by the heterogeneity of the patient population [1]. In the recent ASCO guidelines, treatment including a surgical resection is recommended for a selected subgroup of patients with resectable disease and limited mediastinal nodal involv ement, while patients with unresectable disease should be offered concurrent chemoradiotherapy, followed by consolidation durvalumab in the absence of disease progression [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research